Industry
Biotechnology
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Loading...
Open
1.16
Mkt cap
79M
Volume
741K
High
1.24
P/E Ratio
-1.37
52-wk high
1.72
Low
1.16
Div yield
N/A
52-wk low
0.50
Portfolio Pulse from Benzinga Newsdesk
October 15, 2024 | 12:48 pm
Portfolio Pulse from Benzinga Newsdesk
October 15, 2024 | 12:46 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 8:54 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 12:45 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 12:33 pm
Portfolio Pulse from Benzinga Newsdesk
July 16, 2024 | 1:11 pm
Portfolio Pulse from Benzinga Newsdesk
July 16, 2024 | 1:07 pm
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 1:22 pm
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 1:05 pm
Portfolio Pulse from Avi Kapoor
June 17, 2024 | 5:21 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.